Cargando…

Retrospective Analysis of the Effectiveness of Oral Semaglutide in Type 2 Diabetes Mellitus and Its Effect on Cardiometabolic Parameters in Japanese Clinical Settings

Glucagon-like peptide-1 receptor agonists (GLP-1RA) have a more potent glycated hemoglobin (HbA1c)-lowering effect than existing therapies and are widely used for treating type 2 diabetes mellitus (T2DM). Once-daily oral semaglutide is the world’s first oral GLP-1RA. This study aimed to provide real...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamada, Hodaka, Yoshida, Masashi, Funazaki, Shunsuke, Morimoto, Jun, Tonezawa, Shiori, Takahashi, Asuka, Nagashima, Shuichi, Masahiko, Kimura, Kiyoshi, Otsuka, Hara, Kazuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141082/ https://www.ncbi.nlm.nih.gov/pubmed/37103055 http://dx.doi.org/10.3390/jcdd10040176

Ejemplares similares

Retrospective Study of IDegLira, a New Fixed-Ratio Combination, in Japanese Patients With Type 2 Diabetes Mellitus: Analysis of Background Factors Affecting Effectiveness After 6 Months of Treatment
por: Yamada, Hodaka, et al.
Publicado: (2023)

Effectiveness and Safety of Once-Weekly Semaglutide in Japanese Patients with Type 2 Diabetes in Treatment Intensification: A Retrospective Observational Single-Center Study
por: Yamada, Hodaka, et al.
Publicado: (2022)

Correction: Effectiveness and Safety of Once-Weekly Semaglutide in Japanese Patients with Type 2 Diabetes in Treatment Intensification: A Retrospective Observational Single-Center Study
por: Yamada, Hodaka, et al.
Publicado: (2023)

Spontaneous recovery of immune checkpoint inhibitor‐induced thyroiditis with high free T4 level: A case report
por: Hagiwara, Rie, et al.
Publicado: (2021)

Hypereosinophilia is a predictive biomarker of immune checkpoint inhibitor-induced hypopituitarism in patients with renal cell carcinoma
por: Yamada, Hodaka, et al.
Publicado: (2022)

Sodium–glucose cotransporter 2 inhibitors improved time‐in‐range without increasing hypoglycemia in Japanese patients with type 1 diabetes: A retrospective, single‐center, pilot study
por: Suzuki, Daisuke, et al.
Publicado: (2020)

A novel mechanism of imeglimin‐mediated insulin secretion via the cADPR‐TRP channel pathway
por: Funazaki, Shunsuke, et al.
Publicado: (2021)

Pseudo Intestinal Obstruction Caused by Malignant Paraganglioma
por: Funazaki, Shunsuke, et al.
Publicado: (2021)

Spontaneous pregnancy after full recovery from hypopituitarism caused by lymphocytic hypophysitis
por: Funazaki, Shunsuke, et al.
Publicado: (2018)

Effect of Liraglutide on Type B Insulin Resistance Syndrome and Insulin Allergy in Type 2 Diabetes: A Case Report
por: Matsumoto, Yuko, et al.
Publicado: (2017)

Diabetic ketoacidosis producing extreme hyperkalemia in a patient with type 1 diabetes on hemodialysis
por: Yamada, Hodaka, et al.
Publicado: (2017)

Risk Factors of Hypoglycemic Encephalopathy and Prolonged Hypoglycemia in Patients With Severe Hypoglycemia
por: Saikawa, Rika, et al.
Publicado: (2019)

Association between Urinary Calcium Excretion and Estimated Glomerular Filtration Rate Decline in Patients with Type 2 Diabetes Mellitus: A Retrospective Single-center Observational Study
por: Yamada, Hodaka, et al.
Publicado: (2018)

Background Factors Determining the Introduction and Dosage of Insulin in Women With Gestational Diabetes Mellitus
por: Matsumoto, Yuko, et al.
Publicado: (2019)

The Urinary Phosphate to Serum Fibroblast Growth Factor 23 Ratio, Deemed the Nephron Index, Is a Useful Clinical Index for Early Stage Chronic Kidney Disease in Patients with Type 2 Diabetes: An Observational Pilot Study
por: Yamada, Hodaka, et al.
Publicado: (2018)

Effects of Repaglinide Versus Glimepiride on 1,5-Anhydroglucutol and Glycated Hemoglobin Levels in Japanese Patients With Type 2 Diabetes
por: Yamada, Hodaka, et al.
Publicado: (2018)

Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
por: Wilding, John P. H., et al.
Publicado: (2022)

Effect of Semaglutide on Subclinical Atherosclerosis and Cardiometabolic Compensation: A Real-World Study in Patients with Type 2 Diabetes
por: Patti, Angelo Maria, et al.
Publicado: (2023)

Differential importance of endothelial and hematopoietic cell GLP-1Rs for cardiometabolic versus hepatic actions of semaglutide
por: McLean, Brent A., et al.
Publicado: (2021)

Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses
por: Kosiborod, Mikhail N., et al.
Publicado: (2022)

Oral Semaglutide
por: Bui, Vinh, et al.
Publicado: (2018)

Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)

Corrigendum: Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)

Metabolomics Provides Insights into Renoprotective Effects of Semaglutide in Obese Mice
por: Chen, Xing, et al.
Publicado: (2022)

1984. Effects of Semaglutide on Adipose Tissue in HIV-Associated Lipohypertrophy
por: McComsey, Grace A, et al.
Publicado: (2023)

The Discovery and Development of Liraglutide and Semaglutide
por: Knudsen, Lotte Bjerre, et al.
Publicado: (2019)

Semaglutide for type 2 diabetes
Publicado: (2020)

Semaglutide-associated bullous pemphigoid
por: Burruss, Clayton P., et al.
Publicado: (2021)

Semaglutide-eye-catching results
por: Cigrovski Berkovic, Maja, et al.
Publicado: (2023)

Emerging Anesthesia Risks with Semaglutide
por: Fezza, Reed, et al.
Publicado: (2023)

Efficacy and safety of semaglutide in non-alcoholic fatty liver disease
por: Zhu, Kai, et al.
Publicado: (2023)

Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects
por: Hausner, Helene, et al.
Publicado: (2017)

Effects of Semaglutide on Cardiac Protein Expression and Cardiac Function of Obese Mice
por: Pan, Xiaoyu, et al.
Publicado: (2022)

Effects of Semaglutide and Empagliflozin on Inflammatory Markers in Patients with Type 2 Diabetes
por: Reppo, Ingrid, et al.
Publicado: (2023)

Effect of semaglutide and empagliflozin on cognitive function and hippocampal phosphoproteomic in obese mice
por: Chen, Xiaoyi, et al.
Publicado: (2023)

Oral Semaglutide: Balancing Promising Therapeutics with Adverse Effects and Access Barriers
por: Gunning, Karen
Publicado: (2020)

Eicosapentaenoic acid shows anti-inflammatory effect via GPR120 in 3T3-L1 adipocytes and attenuates adipose tissue inflammation in diet-induced obese mice
por: Yamada, Hodaka, et al.
Publicado: (2017)

Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS)
por: Janić, Miodrag, et al.
Publicado: (2022)

Efficacy and safety of once‐weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index
por: Yabe, Daisuke, et al.
Publicado: (2022)

Acute Kidney Injury Associated With Semaglutide
por: Leehey, David J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hkj5jg2sk01mo1nqiei9mbjp92